EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression

As inhibitors of the histone methyltransferase EZH2 are being evaluated clinically for the treatment of advanced prostate cancer (PrCa), researchers investigated here how EZH2 affects PrCa lineage plasticity.